Assessment of breast lesions with magnetic resonance imaging (MRI) provides a means for lesion detection and diagnosis. Proton (hydrogen-1) magnetic resonance spectroscopy (1H-MRS) has been proposed as a useful diagnostic technique in providing metabolic information of suspicious breast lesions.
Purpose
To determine the clinical significance of in-vivo single voxel 1H-MRS at 3T in the assessment of benign and malignant breast lesions in combination with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
Material and Methods
Twenty-four women with known breast abnormalities from conventional imaging (mammography, ultrasonography) underwent DCE-MRI at a 3T MR scanner and 26 breast lesions were detected. Breast lesions were assessed according BI-RADS classification. Single voxel 1H-MRS was performed after gadolinium administration and choline peak was qualitatively evaluated. All lesions were confirmed histologically from the surgically excised specimens. Sensitivity, specificity, and accuracy of the 1H-MRS, of the BI-RADS classification and of their combination (DCE-MRI + 1H-MRS) were calculated.
Results
Fifteen out of 26 lesions proved to be malignant and 11 proved to be benign. In our study 1H-MRS showed sensitivity 80%, specificity 81.8%, and accuracy 80.7%. DCE-MRI showed sensitivity 100%, specificity 63.6%, and accuracy 84.6%. The combination of DCE-MRI and 1H-MRS provided higher accuracy (96.4%), as well as higher specificity 81.8% compared to BI-RADS classification.
Conclusion
The combined use of 1H-MRS and DCE-MRI found to have improved diagnostic performance in the assessment of equivocal breast lesions. 1H-MRS can be used as a useful adjunct during lesion characterization in clinical routine in cases classified as BI-RADS 3 and 4.
LibermanL. Breast cancer screening with MRI–what are the data for patients at high risk?N Engl J Med2004;351:497–500
2.
RobsonME, OffitK. Breast MRI for women with hereditary cancer risk. JAMA2004;292:1368–70
3.
MorrisEA, LibermanL, BallonDJ, MRI of occult breast carcinoma in a high-risk population. Am J Roentgenol2003;181:619–26
4.
SaslowD, BoetesC, BurkeW, American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin2007;57:75–89
5.
American College of Radiology.Breast imaging reporting and data system: breast imaging atlas. Reston, VA: SAGE Publications, 2003
6.
OrelSG, SchnallMD. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology2001;220:13–30
7.
DanielBL, YenYF, GloverGH, Breast disease: dynamic spiral MR imaging. Radiology1998;209:499–509
8.
KriegeM, BrekelmansCT, BoetesC, Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med2004;351:427–37
9.
LibermanL, MorrisEA, LeeMJ, Breast lesions detected on MR imaging: features and positive predictive value. Am J Roentgenol2002;179:171–8
10.
RoebuckJR, CecilKM, SchnallMD, Human breast lesions: characterization with proton MR spectroscopy. Radiology1998;209:269–75
11.
KvistadKA, BakkenIJ, GribbestadIS, Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging1999;10:159–64
12.
GribbestadIS, SingstadTE, NilsenG, In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging1998;8:1191–7
13.
SijensPE, WijrdemanHK, MoerlandMA, Human breast cancer in vivo: H-1 and P-31 MR spectroscopy at 1.5 T. Radiology1988;169:615–20
14.
YeungDK, CheungHS, TseGM. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy–initial results. Radiology2001;220:40–6
15.
YeungDK, YangWT, TseGM. Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases. Radiology2002;225:190–7
16.
CecilKM, SchnallMD, SiegelmanES, The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat2001;68:45–54
17.
NegendankW. Studies of human tumors by MRS: a review. NMR Biomed1992;5:303–24
18.
TseGM, CheungHS, PangLM, Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. Am J Roentgenol2003;181:1267–72
19.
BartellaL, MorrisEA, DershawDD, Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology2006;239:686–92
20.
BolanPJ, MeisamyS, BakerEH, In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med2003;50:1134–43
21.
GruberS, DebskiBK, PinkerK, Three-dimensional proton MR spectroscopic imaging at 3 T for the differentiation of benign and malignant breast lesions. Radiology2011;261:752–61
22.
Alvarez-LineraJ. 3T MRI: advances in brain imaging. Eur J Radiol2008;67:415–26
23.
KuhlCK, MielcareckP, KlaschikS, Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?Radiology1999;211:101–10
24.
BolanPJ BE, DelaBarreL, MerkleH, Effects of Gd-DTPA on breast 1H MRS at 4T. Proceedings of the 87th annual meeting of the Radiological Society of North America2001
25.
StanwellP, MountfordC. In vivo proton MR spectroscopy of the breast. Radiographics2007;27(Suppl. 1):S253–66
26.
KousiE, TsougosI, VasiouK, Magnetic resonance spectroscopy of the breast at 3T: pre- and post-contrast evaluation for breast lesion characterization. Scientific World Journal2012;2012:754380
27.
MountfordC, RamadanS, StanwellP, MalychaP. Proton MRS of the breast in the clinical setting. NMR Biomed2009;22:54–64
28.
Katz-BrullR, LavinPT, LenkinskiRE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst2002;94:1197–203
29.
AboagyeEO, BhujwallaZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res1999;59:80–4
30.
SingerS, SouzaK, ThillyWG. Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study. Cancer Res1995;55:5140–5
31.
TingYL, SherrD, DeganiH. Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res1996;16:1381–8
32.
Katz-BrullR, SegerD, Rivenson-SegalD, Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res2002;62:1966–70
33.
MurphyPS, Dzik-JuraszAS, LeachMO, The effect of Gd-DTPA on T(1)-weighted choline signal in human brain tumours. Magn Reson Imaging2002;20:127–30
34.
SardanelliF, FaustoA, Di LeoG, In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. Am J Roentgenol2009;192:1608–17
35.
TozakiM, FukumaE. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy?Am J Roentgenol2009;193:840–9
36.
HuJ, YuY, KouZ, A high spatial resolution 1H magnetic resonance spectroscopic imaging technique for breast cancer with a short echo time. Magn Reson Imaging2008;26:360–6
37.
MatsuokaA, MinatoM, HaradaM, Comparison of 3.0-and 1.5-tesla diffusion-weighted imaging in the visibility of breast cancer. Radiat Med2008;26:15–20
38.
MeisamyS, BolanPJ, BakerEH, Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. Radiology2005;236:465–75
39.
VassiouK, KanavouT, VlychouM, Characterization of breast lesions with CE-MR multimodal morphological and kinetic analysis: comparison with conventional mammography and high-resolution ultrasound. Eur J Radiol2009;70:69–76
40.
KuhlCK, SchmutzlerRK, LeutnerCC, Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology2000;215:267–79
41.
MoyL, EliasK, PatelV, Is breast MRI helpful in the evaluation of inconclusive mammographic findings?Am J Roentgenol2009;193:986–93
42.
43.
DorriusMD, PijnappelRM, SijensPE, The negative predictive value of breast Magnetic Resonance Imaging in noncalcified BIRADS 3 lesions. Eur J Radiol2012;81:209–13
44.
BaekHM, ChenJH, YuHJ, Detection of choline signal in human breast lesions with chemical-shift imaging. J Magn Reson Imaging2008;27:1114–21
45.
JacobsMA, BarkerPB, BottomleyPA, Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging2004;19:68–75
46.
JacobsMA, BarkerPB, ArganiP, Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study. J Magn Reson Imaging2005;21:23–8
47.
HaddadinIS, McIntoshA, MeisamyS, Metabolite quantification and high-field MRS in breast cancer. NMR Biomed2009;22:65–76
48.
YehED. Characterization of breast lesions with proton MR spectroscopy. Am J Roentgenol2003;181:1273–4
49.
LenkinskiRE, WangX, ElianM, GoldbergSN. Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast. Magn Reson Med2009;61:1286–92
